Jilin Jian Yisheng Pharmaceutical Co Ltd

Jilin Jian Yisheng Pharmaceutical Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 6.24, suggesting strong short-term liquidity. However, the company has negative net cash after subtracting total debt, which introduces some liquidity risk. In terms of profitability, the company's return on equity (ROE) is 1.3%, and return on assets (ROA) is 0.98%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These metrics suggest that the company is not generating strong returns relative to its equity and asset base, which may indicate inefficiencies or lower pricing power in its product portfolio. The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This lack of geographic diversification increases exposure to domestic economic and regulatory risks. The company's revenue is derived from a mix of pharmaceutical products, but no specific segment breakdown is available in the provided data, limiting the ability to assess performance by therapeutic area or product line. The company's growth trajectory appears modest, with no disclosed revenue growth rates or future projections. The absence of clear growth signals in the financial data suggests a stable but potentially slow-growth business model. The company's operating cash flow of 98.7 million CNY and free cash flow of 12.4 million CNY indicate that it generates positive cash from operations, but the free cash flow is relatively low compared to its operating cash flow, suggesting reinvestment or debt servicing is consuming a significant portion of cash. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The low dilution risk is supported by the absence of recent share issuance and no indication of upcoming equity offerings. However, the company's negative net cash position after debt is a concern, and any unexpected capital needs could force it to raise additional equity or debt, potentially increasing dilution risk. No recent events, such as earnings calls, regulatory filings, or strategic announcements, are disclosed in the provided data, which limits the ability to assess the company's recent performance or strategic direction.